12:00 AM
 | 
Oct 11, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tamiflu oseltamivir: Under FDA review; marketed in Switzerland

University of Virginia researchers and colleagues published in the Journal of the American Medical Association data from two placebo-controlled Phase II/III studies. In a 37-patient prophylaxis study, administration of Tamiflu starting 26 hours before influenza inoculation...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >